Altering the course of schizophrenia: progress and perspectives (Q38759421)

6 September 2017

title

Altering the course of schizophrenia: progress and perspectives (English)

1 reference

6 September 2017

0 references

14

1 reference

6 September 2017

Andreas Meyer-Lindenberg

17

1 reference

6 September 2017

19

1 reference

6 September 2017

25

1 reference

6 September 2017

6

Paolo Fusar-Poli

0 references

Paola Dazzan

5

Paola Dazzan

0 references

Annie Andrieux

Annie Andrieux

2

0 references

Peter J Uhlhaas

Peter Uhlhaas

24

0 references

Marie-Odile Krebs

Marie-Odile Krebs

12

0 references

Marion Leboyer

Marion Leboyer

13

0 references

Oscar Marin

Oscar Marin

15

0 references

René S. Kahn

11

René Kahn

1 reference

6 September 2017

4

Kristin Cadenhead

1 reference

6 September 2017

18

Patrick McGorry

1 reference

6 September 2017

8

Jay Giedd

1 reference

6 September 2017

Michael Spedding

23

0 references

Akira Sawa

22

Akira Sawa

1 reference

6 September 2017

Mark J Millan

1

1 reference

6 September 2017

George Bartzokis

3

1 reference

6 September 2017

Jürgen Gallinat

7

1 reference

6 September 2017

Dennis R Grayson

9

1 reference

6 September 2017

Markus Heinrichs

10

1 reference

6 September 2017

Philippe Marin

16

1 reference

6 September 2017

Michael J Owen

20

1 reference

6 September 2017

Paul Patterson

21

1 reference

6 September 2017

Claes Wahlestedt

26

1 reference

6 September 2017

Daniel Weinberger

27

1 reference

6 September 2017

language of work or name

1 reference

4 March 2016

1 reference

Nature Reviews Drug Discovery

6 September 2017

published in

1 reference

6 September 2017

volume

15

1 reference

6 September 2017

issue

7

1 reference

6 September 2017

page(s)

485-515

1 reference

6 September 2017

cites work

Rethinking schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Neurodevelopmental model of schizophrenia: update 2012

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Global burden of disease in young people aged 10-24 years: a systematic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Mental health. Adolescent mental health--opportunity and obligation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Definition and description of schizophrenia in the DSM-5

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Update on typical and atypical antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Negative symptoms of schizophrenia: clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

A phase II/III trial of bitopertin monotherapy compared with placebo in patients with an acute exacerbation of schizophrenia - results from the CandleLyte study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Development of disease-modifying treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Cortical circuit dysfunction and cognitive deficits in schizophrenia--implications for preemptive interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Transition to adulthood: the critical period for pre-emptive, disease-modifying care for schizophrenia and related disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

EPA guidance on the early intervention in clinical high risk states of psychoses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

A regenerative approach to the treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Defining and labeling disease-modifying treatments for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Drug discovery for autism spectrum disorder: challenges and opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Rationale and first results of developing at-risk (prodromal) criteria for bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Genomic insights into the overlap between psychiatric disorders: implications for research and clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

The current and potential impact of genetics and genomics on neuropsychopharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

The dynamics of DNA methylation in schizophrenia and related psychiatric disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

An epigenetic framework for neurodevelopmental disorders: from pathogenesis to potential therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Epidemiologic studies of exposure to prenatal infection and risk of schizophrenia and autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Immune involvement in schizophrenia and autism: etiology, pathology and animal models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Dysconnectivity in schizophrenia: where are we now?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

The RDoC framework: facilitating transition from ICD/DSM to dimensional approaches that integrate neuroscience and psychopathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Early signs, diagnosis and therapeutics of the prodromal phase of schizophrenia and related psychotic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Bipolar and schizophrenia network for intermediate phenotypes: outcomes across the psychosis continuum

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

The psychosis high-risk state: a comprehensive state-of-the-art review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Brain networks in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

The economic analysis of prevention in mental health programs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Environmental Risk and Protective Factors and Their Influence on the Emergence of Psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Neuroimaging and treatment evidence for clinical staging in psychotic disorders: from the at-risk mental state to chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

EPA guidance on the early detection of clinical high risk states of psychoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Oscillations and neuronal dynamics in schizophrenia: the search for basic symptoms and translational opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Attenuated psychosis syndrome in DSM-5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

The relationship of neurocognition and negative symptoms to social and role functioning over time in individuals at clinical high risk in the first phase of the North American Prodrome Longitudinal Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Theory of mind impairments in first-episode psychosis, individuals at ultra-high risk for psychosis and in first-degree relatives of schizophrenia: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Outcomes of nontransitioned cases in a sample at ultra-high risk for psychosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Coping as a predictor of treatment outcome in people at clinical high risk of psychosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

North American Prodrome Longitudinal Study (NAPLS 2): overview and recruitment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Cortex morphology in first-episode psychosis patients with neurological soft signs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Long-term consequences of adolescent cannabinoid exposure in adult psychopathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Can neuroimaging be used to predict the onset of psychosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Effects of NRG1 and DAOA genetic variation on transition to psychosis in individuals at ultra-high risk for psychosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Uncovering the hidden risk architecture of the schizophrenias: confirmation in three independent genome-wide association studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Stress and inflammation reduce brain-derived neurotrophic factor expression in first-episode psychosis: a pathway to smaller hippocampal volume

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Progressive reduction in cortical thickness as psychosis develops: a multisite longitudinal neuroimaging study of youth at elevated clinical risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Inflammatory molecular signature associated with infectious agents in psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Towards a psychosis risk blood diagnostic for persons experiencing high-risk symptoms: preliminary results from the NAPLS project

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Toward the identification of peripheral epigenetic biomarkers of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Changes in gene expression and methylation in the blood of patients with first-episode psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Stress and neurodevelopmental processes in the emergence of psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Blunted cortisol awakening response in people at ultra high risk of developing psychosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Increased stress-induced dopamine release in psychosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Adolescent stress-induced epigenetic control of dopaminergic neurons via glucocorticoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

HPA axis function and symptoms in adolescents at clinical high risk for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Glutamate and psychosis risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Glutamatergic abnormalities in schizophrenia: a review of proton MRS findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Spine pruning drives antipsychotic-sensitive locomotion via circuit control of striatal dopamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Increased synaptic dopamine function in associative regions of the striatum in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: a PET study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Striatal dopamine D2/3 receptor binding following dopamine depletion in subjects at Ultra High Risk for psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

N-Acetyl-Aspartate Level is Decreased in the Prefrontal Cortex in Subjects At-Risk for Schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Systematic meta-review and quality assessment of the structural brain alterations in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Gray matter alterations in schizophrenia high-risk youth and early-onset schizophrenia: a review of structural MRI findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Using structural neuroimaging to make quantitative predictions of symptom progression in individuals at ultra-high risk for psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Volumetric abnormalities predating the onset of schizophrenia and affective psychoses: an MRI study in subjects at ultrahigh risk of psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Altered striatal functional connectivity in subjects with an at-risk mental state for psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Deficient Suppression of Default Mode Regions during Working Memory in Individuals with Early Psychosis and at Clinical High-Risk for Psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Different duration of at-risk mental state associated with neurofunctional abnormalities. A multimodal imaging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Dysconnectivity, large-scale networks and neuronal dynamics in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Functional dysconnectivity in schizophrenia and its relationship to neural synchrony.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

White matter alterations related to P300 abnormalities in individuals at high risk for psychosis: an MRI-EEG study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Characterization of neurophysiologic and neurocognitive biomarkers for use in genomic and clinical outcome studies of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Forecasting psychosis by event-related potentials-systematic review and specific meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Glutamatergic modulation of auditory information processing in the human brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Language processing abnormalities in adolescents with psychotic-like experiences: an event related potential study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Automatic auditory processing deficits in schizophrenia and clinical high-risk patients: forecasting psychosis risk with mismatch negativity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Incomplete penetrance of NRXN1 deletions in families with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Multimodal voxel-based meta-analysis of structural and functional magnetic resonance imaging studies in those at elevated genetic risk of developing schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Multivariate prediction of emerging psychosis in adolescents at high risk for schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Using genetic, cognitive and multi-modal neuroimaging data to identify ultra-high-risk and first-episode psychosis at the individual level

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Polyunsaturated fatty acids in emerging psychosis: a safer alternative?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Randomized, Double-Blind Trial of Olanzapine Versus Placebo in Patients Prodromally Symptomatic for Psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Randomized Controlled Trial of Interventions for Young People at Ultra-High Risk of Psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Medium term follow-up of a randomized controlled trial of interventions for young people at ultra high risk of psychosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

A randomized controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Preventing progression to first-episode psychosis in early initial prodromal states

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Three-year follow-up of a randomized controlled trial of cognitive therapy for the prevention of psychosis in people at ultrahigh risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Cognitive behavioral therapy for subjects at ultrahigh risk for developing psychosis: a randomized controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Early interventions to prevent psychosis: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Preventing a first episode of psychosis: meta-analysis of randomized controlled prevention trials of 12 month and longer-term follow-ups

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Bayesian analysis of posttest predictive value of screening instruments for the psychosis high-risk state.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

At risk or not at risk? A meta-analysis of the prognostic accuracy of psychometric interviews for psychosis prediction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Red blood cell polyunsaturated fatty acids measured in red blood cells and schizophrenia: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Relationship between membrane fatty acids and cognitive symptoms and information processing in individuals at ultra-high risk for psychosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Update on ω-3 polyunsaturated fatty acids in early-stage psychotic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Omega-3 fatty acid supplementation in adolescents with borderline personality disorder and ultra-high risk criteria for psychosis: a post hoc subgroup analysis of a double-blind, randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Longer-term outcome in the prevention of psychotic disorders by the Vienna omega-3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Possibility of polyunsaturated fatty acids for the prevention and treatment of neuropsychiatric illnesses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Adolescent behavior and dopamine availability are uniquely sensitive to dietary omega-3 fatty acid deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Omega-3 fatty acid deficiency disrupts endocytosis, neuritogenesis, and mitochondrial protein pathways in the mouse hippocampus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Early intervention for psychosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Treatment of Young People With Antipsychotic Medications in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Aripiprazole in the treatment of the psychosis prodrome: an open-label pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Rationale and baseline characteristics of PREVENT: a second-generation intervention trial in subjects at-risk (prodromal) of developing first-episode psychosis evaluating cognitive behavior therapy, aripiprazole, and placebo for the prevention of ps

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Clinical and functional outcomes after 2 years in the early detection and intervention for the prevention of psychosis multisite effectiveness trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Family-focused treatment for adolescents and young adults at high risk for psychosis: results of a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Pilot study of cognitive remediation therapy on cognition in young people at clinical high risk of psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Advancing schizophrenia drug discovery: optimizing rodent models to bridge the translational gap.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Cost-effectiveness of preventing first-episode psychosis in ultra-high-risk subjects: multi-centre randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Omega-3 prevents behavior response and brain oxidative damage in the ketamine model of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Effects of omega-3 dietary supplement in prevention of positive, negative and cognitive symptoms: a study in adolescent rats with ketamine-induced model of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Anti-inflammatory treatment in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Effect of maternal immune activation on the kynurenine pathway in preadolescent rat offspring and on MK801-induced hyperlocomotion in adulthood: amelioration by COX-2 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Microglia-dependent alteration of glutamatergic synaptic transmission and plasticity in the hippocampus during peripheral inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Neonatal intrahippocampal injection of lipopolysaccharide induces deficits in social behavior and prepulse inhibition and microglial activation in rats: Implication for a new schizophrenia animal model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Efficacy and tolerability of minocycline augmentation therapy in schizophrenia: a systematic review and meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Effects of minocycline add-on treatment on brain morphometry and cerebral perfusion in recent-onset schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

The promise of N-acetylcysteine in neuropsychiatry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

N-acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Juvenile antioxidant treatment prevents adult deficits in a developmental model of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Risperidone administered during asymptomatic period of adolescence prevents the emergence of brain structural pathology and behavioral abnormalities in an animal model of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Risperidone pretreatment prevents elevated locomotor activity following neonatal hippocampal lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Effects of risperidone and paliperidone pre-treatment on locomotor response following prenatal immune activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Fluoxetine and aripiprazole treatment following prenatal immune activation exert longstanding effects on rat locomotor response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Chronic administration of risperidone in a rat model of schizophrenia: a behavioural, morphological and molecular study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Evaluating early preventive antipsychotic and antidepressant drug treatment in an infection-based neurodevelopmental mouse model of schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Clozapine administration in adolescence prevents postpubertal emergence of brain structural pathology in an animal model of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Age-dependent regulation of synaptic connections by dopamine D2 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Effects of antipsychotics on dentate gyrus stem cell proliferation and survival in animal models: a critical update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Translating the MAM model of psychosis to humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Peripubertal diazepam administration prevents the emergence of dopamine system hyperresponsivity in the MAM developmental disruption model of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Enhancement of social novelty discrimination by positive allosteric modulators at metabotropic glutamate 5 receptors: adolescent administration prevents adult-onset deficits induced by neonatal treatment with phencyclidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Repeated potentiation of the metabotropic glutamate receptor 5 and the alpha 7 nicotinic acetylcholine receptor modulates behavioural and GABAergic deficits induced by early postnatal phencyclidine (PCP) treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Signaling pathways in schizophrenia: emerging targets and therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Abnormal kalirin signaling in neuropsychiatric disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

PAKs inhibitors ameliorate schizophrenia-associated dendritic spine deterioration in vitro and in vivo during late adolescence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Rescue of fragile X syndrome phenotypes in Fmr1 KO mice by the small-molecule PAK inhibitor FRAX486.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Chronic administration of the neurotrophic agent cerebrolysin ameliorates the behavioral and morphological changes induced by neonatal ventral hippocampus lesion in a rat model of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Prophylactic valproic acid treatment prevents schizophrenia-related behaviour in Disc1-L100P mutant mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Valproic acid (VPA) reduces sensorimotor gating deficits and HDAC2 overexpression in the MAM animal model of schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Exposure to enriched environments during adolescence prevents abnormal behaviours associated with histone deacetylation in phencyclidine-treated mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

The HDAC Inhibitor Phenylbutyrate Reverses Effects of Neonatal Ventral Hippocampal Lesion in Rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Early cognitive experience prevents adult deficits in a neurodevelopmental schizophrenia model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Gamma oscillation deficits and the onset and early progression of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Extracellular matrix abnormalities in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Alterations of prefrontal cortex GABAergic transmission in the complex psychotic-like phenotype induced by adolescent delta-9-tetrahydrocannabinol exposure in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Proof-of-concept randomized controlled trial of pregnenolone in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Pregnenolone treatment reduces severity of negative symptoms in recent-onset schizophrenia: an 8-week, double-blind, randomized add-on two-center trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Modulation of GABAergic transmission in development and neurodevelopmental disorders: investigating physiology and pathology to gain therapeutic perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Characteristics of the cation cotransporter NKCC1 in human brain: alternate transcripts, expression in development, and potential relationships to brain function and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

A randomised controlled trial of bumetanide in the treatment of autism in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Oxytocin-mediated GABA inhibition during delivery attenuates autism pathogenesis in rodent offspring.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Improving emotional face perception in autism with diuretic bumetanide: a proof-of-concept behavioral and functional brain imaging pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Emerging neurotrophic role of GABAB receptors in neuronal circuit development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

GABAB-mediated rescue of altered excitatory-inhibitory balance, gamma synchrony and behavioral deficits following constitutive NMDAR-hypofunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

GABAB/NMDA receptor interaction in the regulation of extracellular dopamine levels in rodent prefrontal cortex and striatum

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Kv3.1-containing K(+) channels are reduced in untreated schizophrenia and normalized with antipsychotic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Modelling prefrontal cortex deficits in schizophrenia: implications for treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Neuregulin-ERBB signaling in the nervous system and neuropsychiatric diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Reversal of behavioral deficits and synaptic dysfunction in mice overexpressing neuregulin 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Transient exposure of neonatal mice to neuregulin-1 results in hyperdopaminergic states in adulthood: implication in neurodevelopmental hypothesis for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Neuregulin 1-ErbB4-PI3K signaling in schizophrenia and phosphoinositide 3-kinase-p110δ inhibition as a potential therapeutic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

The emerging role of MicroRNA in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Stress-induced perinatal and transgenerational epigenetic programming of brain development and mental health

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Brain-derived neurotrophic factor epigenetic modifications associated with schizophrenia-like phenotype induced by prenatal stress in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

DNA methylation changes in the postmortem dorsolateral prefrontal cortex of patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

DNA-methyltransferase1 (DNMT1) binding to CpG rich GABAergic and BDNF promoters is increased in the brain of schizophrenia and bipolar disorder patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Gadd45a promotes DNA demethylation through TDG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Prenatal MAM administration affects histone H3 methylation in postnatal life in the rat medial prefrontal cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Maturation of the human dorsolateral prefrontal cortex coincides with a dynamic shift in microRNA expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

MicroRNAs: Small molecules with big roles in neurodevelopment and diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Molecular profiles of parvalbumin-immunoreactive neurons in the superior temporal cortex in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

MicroRNA-9 and microRNA-326 regulate human dopamine D2 receptor expression, and the microRNA-mediated expression regulation is altered by a genetic variant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Multimodal magnetic resonance imaging assessment of white matter aging trajectories over the lifespan of healthy individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Mechanisms regulating the development of oligodendrocytes and central nervous system myelin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Schizophrenia: breakdown in the well-regulated lifelong process of brain development and maturation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Oligodendroglial alterations and the role of microglia in white matter injury: relevance to schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Not on speaking terms: hallucinations and structural network disconnectivity in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Neuroimaging evidence for the deficit subtype of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Improving myelin/oligodendrocyte-related dysfunction: a new mechanism of antipsychotics in the treatment of schizophrenia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Understanding aberrant white matter development in schizophrenia: an avenue for therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Neuroglialpharmacology: myelination as a shared mechanism of action of psychotropic treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Neuroconnectivity and valproic acid: the myelin hypothesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

G protein-coupled receptor 30 contributes to improved remyelination after cuprizone-induced demyelination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Abnormal synaptic pruning in schizophrenia: Urban myth or reality?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Phagocytic glial cells: sculpting synaptic circuits in the developing nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Dendritic spine pathology in neuropsychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

GluN3A promotes dendritic spine pruning and destabilization during postnatal development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Molecular signature of rapid estrogen regulation of synaptic connectivity and cognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Deficient neuron-microglia signaling results in impaired functional brain connectivity and social behavior.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Loss of mTOR-dependent macroautophagy causes autistic-like synaptic pruning deficits

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Major histocompatibility complex I in brain development and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Molecular mechanisms and timing of cortical immune activation in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Neuroinflammation and white matter pathology in schizophrenia: systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Stress in puberty unmasks latent neuropathological consequences of prenatal immune activation in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Modeling an autism risk factor in mice leads to permanent immune dysregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Prenatal immune activation and subsequent peripubertal stress as a new model of schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Toxoplasma gondii and other risk factors for schizophrenia: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Human endogenous retrovirus type W (HERV-W) in schizophrenia: a new avenue of research at the gene-environment interface

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Schizophrenia and the gut–brain axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Microbiota and neurodevelopmental windows: implications for brain disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Is adolescence a sensitive period for sociocultural processing?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

The neurobiology of adolescence: changes in brain architecture, functional dynamics, and behavioral tendencies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Modelling schizophrenia using human induced pluripotent stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Synaptic dysregulation in a human iPS cell model of mental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Translation: screening for novel therapeutics with disease-relevant cell types derived from human stem cell models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Hippocampal-dorsolateral prefrontal coupling as a species-conserved cognitive mechanism: a human translational imaging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Functional magnetic resonance imaging of intrinsic brain networks for translational drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Neurodevelopmental liability to schizophrenia: the complex mediating role of age at onset and premorbid adjustment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Schizophrenia and Depression Co-Morbidity: What We have Learned from Animal Models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Contribution of sex hormones to gender differences in schizophrenia: A review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

The role of intranasal oxytocin in the treatment of patients with schizophrenia: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Therapeutic utility of non-peptidic CRF1 receptor antagonists in anxiety, depression, and stress-related disorders: Evidence from animal models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Dopamine D₃ receptor antagonism--still a therapeutic option for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Serotonin receptors as targets for drugs useful to treat psychosis and cognitive impairment in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

S32006, a novel 5-HT2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Glycine treatment of the risk syndrome for psychosis: report of two pilot studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Glial D-serine gates NMDA receptors at excitatory synapses in prefrontal cortex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

D-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double-blind, placebo-controlled, randomised parallel group mechanistic proof-of-concept trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Duration of untreated psychosis as predictor of long-term outcome in schizophrenia: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Preventing the second episode: a systematic review and meta-analysis of psychosocial and pharmacological trials in first-episode psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Effects of aripiprazole and haloperidol on progression to schizophrenia-like behavioural abnormalities and apoptosis in rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Phencyclidine-induced loss of asymmetric spine synapses in rodent prefrontal cortex is reversed by acute and chronic treatment with olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Does treatment of schizophrenia with antipsychotic medications eliminate or reduce psychosis? A 20-year multi-follow-up study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Pharmacotherapy challenges in patients with first-episode psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

A systematic review and meta-analysis of recovery in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

The RAISE early treatment program for first-episode psychosis: background, rationale, and study design

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

The RAISE Connection Program for Early Psychosis: Secondary Outcomes and Mediators and Moderators of Improvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Learning from the past and looking to the future: Emerging perspectives for improving the treatment of psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Structure of the psychotic disorders classification in DSM-5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Addiction is a Reward Deficit and Stress Surfeit Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Pre-treatment, baseline, and outcome differences between early-onset and adult-onset psychosis in an epidemiological cohort of 636 first-episode patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Cultures for mental health care of young people: an Australian blueprint for reform

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Adolescence: a foundation for future health

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Outreach and support in south London (OASIS), 2001-2011: ten years of early diagnosis and treatment for young individuals at high clinical risk for psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Designing youth mental health services for the 21st century: examples from Australia, Ireland and the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

First-episode psychosis patients recruited into treatment via early detection teams versus ordinary pathways: course and health service use during 5 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Phencyclidine-induced social withdrawal results from deficient stimulation of cannabinoid CB₁ receptors: implications for schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Cannabidiol as a potential treatment for psychosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Adolescent cannabinoid exposure permanently suppresses cortical oscillations in adult mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Adolescent brain development, substance use, and psychotherapeutic change

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Cannabinoid- and lysophosphatidylinositol-sensitive receptor GPR55 boosts neurotransmitter release at central synapses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Occupancy of brain dopamine D3 receptors and drug craving: a translational approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Kappa opioid receptors regulate stress-induced cocaine seeking and synaptic plasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Translational and reverse translational research on the role of stress in drug craving and relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

5-HT(6) receptor recruitment of mTOR as a mechanism for perturbed cognition in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

5-HT6 Receptor Antagonists: Potential Efficacy for the Treatment of Cognitive Impairment in Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

On the interaction between drugs of abuse and adolescent social behavior.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Modulating social behavior with oxytocin: how does it work? What does it mean?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Towards improved animal models for evaluating social cognition and its disruption in schizophrenia: the CNTRICS initiative

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Oxytocin-augmented social cognitive skills training in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Oxytocin administration enhances controlled social cognition in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

A meta-analysis and theoretical critique of oxytocin and psychosis: prospects for attachment and compassion in promoting recovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Selective blockade of dopamine D3 receptors enhances while D2 receptor antagonism impairs social novelty discrimination and novel object recognition in rats: a key role for the prefrontal cortex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

FOXG1-Dependent Dysregulation of GABA/Glutamate Neuron Differentiation in Autism Spectrum Disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Thinking out of the dish: what to learn about cortical development using pluripotent stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Modeling hippocampal neurogenesis using human pluripotent stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Altered WNT Signaling in Human Induced Pluripotent Stem Cell Neural Progenitor Cells Derived from Four Schizophrenia Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Modeling a genetic risk for schizophrenia in iPSCs and mice reveals neural stem cell deficits associated with adherens junctions and polarity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Functional cortical neurons and astrocytes from human pluripotent stem cells in 3D culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Concise review: Patient-derived olfactory stem cells: new models for brain diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Genome-wide profiling of multiple histone methylations in olfactory cells: further implications for cellular susceptibility to oxidative stress in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

MicroRNA-382 expression is elevated in the olfactory neuroepithelium of schizophrenia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Behavioral phenotypes in schizophrenic animal models with multiple combinations of genetic and environmental factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

The poly(I:C)-induced maternal immune activation model in preclinical neuropsychiatric drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Caution When Diagnosing Your Mouse With Schizophrenia: The Use and Misuse of Model Animals for Understanding Psychiatric Disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Inflammation and the two-hit hypothesis of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Phenotypic effects of repeated psychosocial stress during adolescence in mice mutant for the schizophrenia risk gene neuregulin-1: a putative model of gene × environment interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Neonatal phencyclidine administration and post-weaning social isolation as a dual-hit model of 'schizophrenia-like' behaviour in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Adolescent onset of cortical disinhibition in schizophrenia: insights from animal models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Behavioural alterations relevant to developmental brain disorders in mice with neonatally induced ventral hippocampal lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Preweaning sensorimotor deficits and adolescent hypersociability in Grin1 knockdown mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Interneuron dysfunction in psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Adolescents at ultra-high risk for psychosis: long-term outcome of individuals who recover from their at-risk state

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Improving the clinical prediction of psychosis by combining ultra-high risk criteria and cognitive basic symptoms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Early detection and intervention evaluation for people at risk of psychosis: multisite randomised controlled trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

NEURAPRO-E study protocol: a multicentre randomized controlled trial of omega-3 fatty acids and cognitive-behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

The interneuron energy hypothesis: Implications for brain disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Neuroimmune biomarkers in schizophrenia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Using human brain imaging studies as a guide toward animal models of schizophrenia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Confidence and psychosis: a neuro-computational account of contingency learning disruption by NMDA blockade.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

SHANK3 and IGF1 restore synaptic deficits in neurons from 22q13 deletion syndrome patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Abnormal Gamma Oscillations in N-Methyl-D-Aspartate Receptor Hypofunction Models of Schizophrenia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.28

Preventive pharmacological treatment --an evolving new concept in schizophrenia

31 March 2020

1 reference

12 December 2020

Schizophrenia and abnormal brain network hubs

1 reference

12 December 2020

Cerebrolysin for vascular dementia

1 reference

12 December 2020

Implementing Coordinated Specialty Care for Early Psychosis: The RAISE Connection Program

1 reference

12 December 2020

Electrophysiological and neuropsychological predictors of conversion to schizophrenia in at-risk subjects

1 reference

12 December 2020

Anna-Monika Award Lecture, DGPPN Kongress, 2013: the role of the hypothalamic-pituitary-adrenal (HPA) axis in the pathogenesis of psychotic major depression

1 reference

12 December 2020

Selective overexpression of dopamine D3 receptors in the striatum disrupts motivation but not cognition.

1 reference

12 December 2020

Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial

1 reference

12 December 2020

Effect of probiotic supplementation on schizophrenia symptoms and association with gastrointestinal functioning: a randomized, placebo-controlled trial

1 reference

12 December 2020

Functional neuroimaging and schizophrenia: a view towards effective connectivity modeling and polygenic risk

1 reference

12 December 2020

Neurological soft signs in first-episode psychosis: a systematic review

1 reference

12 December 2020

Development of a blood-based molecular biomarker test for identification of schizophrenia before disease onset

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRD.2016.28

1 reference

6 September 2017

1 reference